×
S&P 500   3,780.75 (-0.12%)
DOW   30,727.87 (-0.15%)
QQQ   278.18 (-0.75%)
AAPL   136.25 (-0.34%)
MSFT   255.69 (-0.44%)
META   155.84 (-3.36%)
GOOGL   2,144.19 (-1.61%)
AMZN   107.64 (+1.35%)
TSLA   670.81 (-0.39%)
NVDA   145.34 (-4.12%)
NIO   21.09 (-2.90%)
BABA   114.84 (+1.02%)
AMD   73.16 (-4.33%)
MU   52.24 (-5.50%)
CGC   2.78 (-2.46%)
T   20.95 (-0.05%)
GE   62.49 (-1.85%)
F   11.12 (-0.09%)
DIS   94.50 (+0.11%)
AMC   13.45 (-0.74%)
PFE   51.49 (-1.79%)
PYPL   69.90 (+0.09%)
NFLX   175.65 (+0.45%)
S&P 500   3,780.75 (-0.12%)
DOW   30,727.87 (-0.15%)
QQQ   278.18 (-0.75%)
AAPL   136.25 (-0.34%)
MSFT   255.69 (-0.44%)
META   155.84 (-3.36%)
GOOGL   2,144.19 (-1.61%)
AMZN   107.64 (+1.35%)
TSLA   670.81 (-0.39%)
NVDA   145.34 (-4.12%)
NIO   21.09 (-2.90%)
BABA   114.84 (+1.02%)
AMD   73.16 (-4.33%)
MU   52.24 (-5.50%)
CGC   2.78 (-2.46%)
T   20.95 (-0.05%)
GE   62.49 (-1.85%)
F   11.12 (-0.09%)
DIS   94.50 (+0.11%)
AMC   13.45 (-0.74%)
PFE   51.49 (-1.79%)
PYPL   69.90 (+0.09%)
NFLX   175.65 (+0.45%)
S&P 500   3,780.75 (-0.12%)
DOW   30,727.87 (-0.15%)
QQQ   278.18 (-0.75%)
AAPL   136.25 (-0.34%)
MSFT   255.69 (-0.44%)
META   155.84 (-3.36%)
GOOGL   2,144.19 (-1.61%)
AMZN   107.64 (+1.35%)
TSLA   670.81 (-0.39%)
NVDA   145.34 (-4.12%)
NIO   21.09 (-2.90%)
BABA   114.84 (+1.02%)
AMD   73.16 (-4.33%)
MU   52.24 (-5.50%)
CGC   2.78 (-2.46%)
T   20.95 (-0.05%)
GE   62.49 (-1.85%)
F   11.12 (-0.09%)
DIS   94.50 (+0.11%)
AMC   13.45 (-0.74%)
PFE   51.49 (-1.79%)
PYPL   69.90 (+0.09%)
NFLX   175.65 (+0.45%)
S&P 500   3,780.75 (-0.12%)
DOW   30,727.87 (-0.15%)
QQQ   278.18 (-0.75%)
AAPL   136.25 (-0.34%)
MSFT   255.69 (-0.44%)
META   155.84 (-3.36%)
GOOGL   2,144.19 (-1.61%)
AMZN   107.64 (+1.35%)
TSLA   670.81 (-0.39%)
NVDA   145.34 (-4.12%)
NIO   21.09 (-2.90%)
BABA   114.84 (+1.02%)
AMD   73.16 (-4.33%)
MU   52.24 (-5.50%)
CGC   2.78 (-2.46%)
T   20.95 (-0.05%)
GE   62.49 (-1.85%)
F   11.12 (-0.09%)
DIS   94.50 (+0.11%)
AMC   13.45 (-0.74%)
PFE   51.49 (-1.79%)
PYPL   69.90 (+0.09%)
NFLX   175.65 (+0.45%)
NASDAQ:OYST

Oyster Point Pharma Stock Forecast, Price & News

$4.54
+0.21 (+4.85%)
(As of 07/1/2022 11:58 AM ET)
Add
Compare
Today's Range
$4.42
$4.54
50-Day Range
$3.60
$7.26
52-Week Range
$3.46
$19.98
Volume
769 shs
Average Volume
175,994 shs
Market Capitalization
$121.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00
30 days | 90 days | 365 days | Advanced Chart

Receive OYST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter.

OYST Stock Forecast (MarketRank)

Overall MarketRank

1.86 out of 5 stars

Medical Sector

730th out of 1,429 stocks

Biological Products, Except Diagnostic Industry

117th out of 217 stocks

Analyst Opinion: 3.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
Oyster Point Pharma logo

About Oyster Point Pharma (NASDAQ:OYST)

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

OYST Stock News Headlines

Oyster Point Pharma (NASDAQ:OYST) Stock Price Down 7.2%
Oyster Point Pharma Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OYST
Fax
N/A
Employees
303
Year Founded
N/A

Company Calendar

Last Earnings
5/05/2022
Today
7/01/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$23.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+318.5%
Consensus Rating
Hold
Rating Score (0-4)
2
Research Coverage
1 Analysts

Profitability

Net Income
$-100.66 million
Pretax Margin
-475.87%

Debt

Sales & Book Value

Annual Sales
$24.54 million
Book Value
$3.80 per share

Miscellaneous

Free Float
21,895,000
Market Cap
$121.08 million
Optionable
Not Optionable
Beta
1.02














Oyster Point Pharma Frequently Asked Questions

Should I buy or sell Oyster Point Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oyster Point Pharma in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Oyster Point Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OYST, but not buy additional shares or sell existing shares.
View analyst ratings for Oyster Point Pharma
or view top-rated stocks.

What is Oyster Point Pharma's stock price forecast for 2022?

1 brokerages have issued 1 year target prices for Oyster Point Pharma's shares. Their OYST stock forecasts range from $15.00 to $23.00. On average, they anticipate Oyster Point Pharma's stock price to reach $19.00 in the next year. This suggests a possible upside of 318.5% from the stock's current price.
View analysts' price targets for Oyster Point Pharma
or view top-rated stocks among Wall Street analysts.

How has Oyster Point Pharma's stock performed in 2022?

Oyster Point Pharma's stock was trading at $18.26 at the beginning of the year. Since then, OYST shares have decreased by 75.1% and is now trading at $4.54.
View the best growth stocks for 2022 here
.

When is Oyster Point Pharma's next earnings date?

Oyster Point Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Oyster Point Pharma
.

How were Oyster Point Pharma's earnings last quarter?

Oyster Point Pharma, Inc. (NASDAQ:OYST) released its quarterly earnings results on Thursday, May, 5th. The company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.75) by $0.05. The company had revenue of $2.70 million for the quarter, compared to analysts' expectations of $2.06 million. During the same period in the previous year, the business posted ($0.73) earnings per share.
View Oyster Point Pharma's earnings history
.

Who are Oyster Point Pharma's key executives?

Oyster Point Pharma's management team includes the following people:
  • Dr. Jeffrey Nau MMS, Ph.D., Pres, CEO & Director (Age 47, Pay $962.85k)
  • Mr. Daniel Lochner M.B.A., Chief Financial Officer (Age 39, Pay $642k)
  • Mr. John Snisarenko M.B.A., Chief Commercial Officer (Age 59, Pay $634.95k)
  • Mr. George Donato M.B.A., Sr. VP of CMC & Operations
  • Dr. Eric Carlson Ph.D., Chief Scientific Officer
  • Arty Ahmed, VP of Investor relations
  • Mr. Barry Rosenfeld J.D., Sr. VP & Gen. Counsel
  • Ms. Raegan A. McClain CCEP, J.D., L.L.M., Chief Compliance & Privacy Officer
  • Ms. Karen Castillo-Paff, VP of Communications & PR
  • Mr. Dave Benadon, Chief HR Officer

What other stocks do shareholders of Oyster Point Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oyster Point Pharma investors own include OPKO Health (OPK), Pfizer (PFE), Akero Therapeutics (AKRO), Walt Disney (DIS), Energy Transfer (ET), Fulcrum Therapeutics (FULC), Johnson & Johnson (JNJ), (NGM), Occidental Petroleum (OXY) and vTv Therapeutics (VTVT).

When did Oyster Point Pharma IPO?

(OYST) raised $85 million in an initial public offering on Thursday, October 31st 2019. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO.

What is Oyster Point Pharma's stock symbol?

Oyster Point Pharma trades on the NASDAQ under the ticker symbol "OYST."

How do I buy shares of Oyster Point Pharma?

Shares of OYST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oyster Point Pharma's stock price today?

One share of OYST stock can currently be purchased for approximately $4.54.

How much money does Oyster Point Pharma make?

Oyster Point Pharma (NASDAQ:OYST) has a market capitalization of $121.08 million and generates $24.54 million in revenue each year. The company earns $-100.66 million in net income (profit) each year or ($4.94) on an earnings per share basis.

How many employees does Oyster Point Pharma have?

Oyster Point Pharma employs 303 workers across the globe.

How can I contact Oyster Point Pharma?

Oyster Point Pharma's mailing address is 202 CARNEGIE CENTER SUITE 109, PRINCETON NJ, 08540. The official website for Oyster Point Pharma is www.oysterpointrx.com. The company can be reached via phone at 609-382-9032 or via email at [email protected].

This page (NASDAQ:OYST) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.